https://www.selleckchem.com/pr....oducts/Nevirapine(Vi
This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR /HER2 ) metastatic breast cancer (mBC) patients during the compassionate use program in Spain from February 2015 to November 2017. Patient data were collected retrospectively from 35 hospitals in Spain. Patients with HR /HER2 mBC who had progressed on ≥4 treatments for advanced disease were eligible. A total of 219 patients received palbociclib
Like
Comment
Share
